Opinion
Video
Optimizing CAR T for R/R CLL: Timing and Treatment Sequencing Strategies
Author(s):
Experts discuss when to consider chimeric antigen receptor T-cell therapy (CAR T) for relapsed/refractory chronic lymphocytic leukemia (R/R CLL) patients and how to sequence CAR T and pirtobrutinib in clinical practice for those who have previously received both covalent Bruton tyrosine kinase (cBTK) inhibitor– and BCL2 inhibitor–containing regimens.
Video content above is prompted by the following:
- Shifting focus to CLL, Dr Riedell,at what point do you consider CAR T-cell therapy for your R/R CLL patients?
- How do you sequence between CAR T and pirtobrutinib in your clinical practice for those who have previously received both cBTK inhibitor– and BCL2 inhibitor–containing regimens?
Latest CME
View All
Video
Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge
May 14th 2025 - May 15th 2026
online-activity
Video
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Arizona
May 13th 2025 - Jun 18th 2025
online-activity
Video
16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™
May 9th 2025 - Jun 14th 2025
online-activity
Related Content
.jpg?fit=crop&auto=format)
